spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:   OBD 

 HSMN NewsFeed - 15 Jul 2010
Adolor Corporation Announces Restructuring
Biopharmaceuticals
 HSMN NewsFeed - 2 Sep 2008
Adolor Regains Rights to Entereg(R) (alvimopan) for OBD
Biopharmaceuticals
 HSMN NewsFeed - 3 Jul 2008
Adolor Provides Update on Entereg(R) (alvimopan) OBD Program
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Jun 2008
Adolor Promotes Dr. Lee Techner to Vice President, Medical Affairs and Medical Director
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 May 2008
Adolor and GlaxoSmithKline Announce FDA Approval of Entereg(R) (alvimopan) for the Management of Postoperative Ileus (POI)
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 May 2008
Adolor Provides Regulatory Update on Entereg(R) (alvimopan)
Biopharmaceuticals
 HSMN NewsFeed - 8 Feb 2008
FDA Extends Review of NDA for ENTEREG(R) (alvimopan)
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Jan 2008
Adolor and GlaxoSmithKline Report Favorable FDA Advisory Committee Meeting for ENTEREG(R) (alvimopan) for the Management of Postoperative Ileus in Bowel Resection
Biopharmaceuticals
 HSMN NewsFeed - 28 Nov 2007
Adolor and GlaxoSmithKline Announce FDA Advisory Committee to Review Entereg(R) (alvimopan) for the Management of Postoperative Ileus (POI)
Biopharmaceuticals Surgery
 HSMN NewsFeed - 13 Sep 2007
FDA To Continue Its Review of Requests for Release of Clinical Hold on alvimopan (Entereg(R))
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Sep 2007
Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
Biopharmaceuticals
 HSMN NewsFeed - 28 Aug 2007
FDA Accepts for Review Complete Response to Approvable Letter for Entereg(R) (alvimopan) for POI
Biopharmaceuticals Surgery FDA
 HSMN NewsFeed - 11 Jun 2007
GSK and Adolor Update Alvimopan (Entereg/Entrareg(R)) Development Program
Biopharmaceuticals
 HSMN NewsFeed - 9 Apr 2007
GSK and Adolor Announce Preliminary Results from Phase 3 Safety Study of Alvimopan (ENTEREG/ENTRAREG(R))
Biopharmaceuticals
 HSMN NewsFeed - 6 Nov 2006
FDA Issues Approvable Letter for Entereg(R) (alvimopan) for POI
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 Oct 2006
Adolor Corporation Discontinues Development of Sterile Lidocaine Patch
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 28 Jun 2006
Adolor Corporation Appoints Scott T. Megaffin as Vice President, Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 May 2006
Adolor's Complete Response to Approvable Letter for Entereg(R) (Alvimopan) in POI Accepted for Review by FDA
Biopharmaceuticals Gastroenterology Surgery FDA
Return to NewsFeed  

 Additional items found! 8

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 8 additional stories matching:
OBD
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!